Pre-made Pasotuxizumab benchmark antibody ( Bispecific scFv, anti-FOLH1/GCPII;CD3E therapeutic antibody, Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Pasotuxizumab biosimilar, Bispecific scFv, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Pasotuxizumab is a PSMA x CD3 BiTE immune therapy that mediates killing of tumor cells by T cells.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-429-1mg	1mg	Inquiry
GMP-Bios-ab-429-10mg	10mg	Inquiry
GMP-Bios-ab-429-100mg	100mg	Inquiry
GMP-Bios-ab-429-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Pasotuxizumab biosimilar, Bispecific scFv, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody
INN Name	Pasotuxizumab
Target	GCPII;CD3E
Format	Bispecific scFv
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	na
VD LC	Kappa;Lambda
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2014
Year Recommended	2015
Companies	Amgen;Bayer HealthCare Pharmaceuticals;Micromet Inc
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Prostate cancer
Development Tech	na